The purpose of this study is to find out how the brain learns to move in infants with and without brain injury. Some infants with brain injury later have cerebral palsy (CP), a condition that makes it hard for infants to learn how to move and control their balance, and others do not. Three groups of infants will participate- infants who had a brain injury and are at high risk for CP, infants who had a brain injury and are not at high risk for CP, and infants who are typically developing.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more. Eligible participants will be given either erenumab or placebo, assigned randomly (like the flip of a coin), followed by an open-label phase in which all participants receive erenumab. Erenumab has been FDA-approved for use in adults to decrease the frequency of migraine. Patients may be eligible to participate if they have had migraine for at least one year, and agree to come to CHOP's main hospital for several study visits. Patients whose headache started suddenly (New Daily Persistent Headache), patients whose headache started after a concussion (Post-Traumatic Headache), and patients with severe depression are not eligible for this study.